Factors that predict glycaemic response to sodium‐glucose linked transporter (SGLT) inhibitors

• DOI: 10.1111/imj.14805
• Publication Date: 2020-02-24T20:25:45Z
• Authors: Amy L. Harding; Naiara Bediaga; Anna Galligan; Peter G. Colman; Spiros Fourlanos; John M. Wentworth
• Keywords: Adult; Male; Sodium; 610; 6. Clean water; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Female; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors

Abstract Aim To determine the clinical and biochemical variables associated with change in HbA1c patients type 2 diabetes who start sodium‐glucose linked transporter (SGLT) inhibitor therapy. Methods We performed a prospective cohort study (ACTRN12616000833460) of 48 adults (30 male, 18 female) attended tertiary hospital clinic. Fasting serum urine samples, collected during clinic visits prior to at 1, 12 24 weeks after commencing SGLT treatment, were analysed for HbA1c, electrolytes, urea, creatinine glucose. Results After weeks, therapy was respective median (97% CI) decreases weight, blood pressure, albumin/creatinine ratio 3.0 (1.7–3.4) kg, 8 (2–16)/4 (3–9) mmHg, 6 (3–14) mmol/mol 0.69 (0.18–1.8) mg/mmol. These effects persisted weeks. Urinary frequency genitourinary infection common adverse effects. Baseline eGFR independently predicted ΔHbA1c whereas only baseline fractional glucose excretion fasting 1 week starting did not contribute prediction glycaemic response. Conclusions setting improvements comparable those observed trials but higher incidence side‐effects. eGFR, excretion,